JP2012532106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532106A5 JP2012532106A5 JP2012517814A JP2012517814A JP2012532106A5 JP 2012532106 A5 JP2012532106 A5 JP 2012532106A5 JP 2012517814 A JP2012517814 A JP 2012517814A JP 2012517814 A JP2012517814 A JP 2012517814A JP 2012532106 A5 JP2012532106 A5 JP 2012532106A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- trifluoromethyl
- trans
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22170809P | 2009-06-30 | 2009-06-30 | |
| US61/221,708 | 2009-06-30 | ||
| PCT/US2010/040125 WO2011002696A1 (en) | 2009-06-30 | 2010-06-28 | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532106A JP2012532106A (ja) | 2012-12-13 |
| JP2012532106A5 true JP2012532106A5 (enExample) | 2013-08-15 |
| JP5689875B2 JP5689875B2 (ja) | 2015-03-25 |
Family
ID=42352717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517814A Expired - Fee Related JP5689875B2 (ja) | 2009-06-30 | 2010-06-28 | トランス−４−［［（５ｓ）−５−［［［３，５−ビス（トリフルオロメチル）フェニル］メチル］（２−メチル−２ｈ−テトラゾール−５−イル）アミノ］−２，３，４，５−テトラヒドロ−７，９−ジメチル−１ｈ−１−ベンゾアゼピン−１−イル］メチル］−シクロヘキサンカルボン酸 |
Country Status (37)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0512523A (pt) * | 2004-06-24 | 2008-03-11 | Lilly Co Eli | composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| SG10201605304VA (en) * | 2011-07-08 | 2016-08-30 | Novartis Ag | Method of treating atherosclerosis in high triglyceride subjects |
| CN103958501B (zh) * | 2012-07-16 | 2016-08-17 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
| PL2943474T3 (pl) | 2013-01-31 | 2017-12-29 | Chong Kun Dang Pharmaceutical Corp. | Związki stanowiące pochodne cycloheksenu podstawionego biarylem lub heterocyklicznym biarylem jako inhibitory cetp |
| CN105017085B (zh) * | 2014-04-28 | 2018-06-29 | 中国科学院上海药物研究所 | 一类kcnq钾通道激动剂、其制备方法和用途 |
| ES2825675T3 (es) | 2014-07-30 | 2021-05-17 | Hoffmann La Roche | Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| CN108456213B (zh) * | 2017-02-22 | 2021-01-15 | 浙江九洲药业股份有限公司 | 一种3-氟-4-羟基环己烷羧酸酯的制备方法 |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4948639B1 (enExample) | 1970-12-15 | 1974-12-23 | ||
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| CA2445693A1 (en) | 2001-04-30 | 2002-11-07 | Pfizer Products Inc. | Compounds useful as intermediates for 4-aminoquinoline derivatives |
| US7332514B2 (en) | 2002-08-30 | 2008-02-19 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| KR20050055747A (ko) | 2002-10-04 | 2005-06-13 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료용의 ｐｇｄ2 수용체 길항제 |
| WO2004078730A2 (en) | 2003-03-04 | 2004-09-16 | Takasago International Corporation | Method for producing optically active amines |
| US20040204450A1 (en) | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| AU2004282101A1 (en) | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| ATE402180T1 (de) | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| CN1972927A (zh) * | 2004-06-24 | 2007-05-30 | 伊莱利利公司 | 用于治疗血脂障碍的化合物和方法 |
| BRPI0512523A (pt) * | 2004-06-24 | 2008-03-11 | Lilly Co Eli | composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
-
2010
- 2010-06-23 TW TW099120507A patent/TWI450896B/zh not_active IP Right Cessation
- 2010-06-23 AR ARP100102219A patent/AR077208A1/es unknown
- 2010-06-24 JO JO2010211A patent/JO2867B1/en active
- 2010-06-28 SI SI201030386T patent/SI2448933T1/sl unknown
- 2010-06-28 RS RS20130453A patent/RS52988B/sr unknown
- 2010-06-28 MA MA34490A patent/MA33385B1/fr unknown
- 2010-06-28 DK DK10728558.7T patent/DK2448933T3/da active
- 2010-06-28 US US12/824,355 patent/US8329688B2/en not_active Expired - Fee Related
- 2010-06-28 KR KR1020117031449A patent/KR101404893B1/ko not_active Expired - Fee Related
- 2010-06-28 PE PE2011002156A patent/PE20120538A1/es not_active Application Discontinuation
- 2010-06-28 HR HRP20130950AT patent/HRP20130950T1/hr unknown
- 2010-06-28 PT PT107285587T patent/PT2448933E/pt unknown
- 2010-06-28 ES ES10728558T patent/ES2435293T3/es active Active
- 2010-06-28 BR BRPI1011931A patent/BRPI1011931A2/pt not_active IP Right Cessation
- 2010-06-28 US US13/318,874 patent/US8299060B2/en not_active Expired - Fee Related
- 2010-06-28 EP EP10728558.7A patent/EP2448933B1/en active Active
- 2010-06-28 UA UAA201115555A patent/UA109409C2/ru unknown
- 2010-06-28 EA EA201270099A patent/EA020600B1/ru not_active IP Right Cessation
- 2010-06-28 ME MEP-2013-114A patent/ME01606B/me unknown
- 2010-06-28 CN CN201080029957.9A patent/CN102639528B/zh not_active Expired - Fee Related
- 2010-06-28 MY MYPI2011006319A patent/MY157121A/en unknown
- 2010-06-28 NZ NZ596820A patent/NZ596820A/xx not_active IP Right Cessation
- 2010-06-28 JP JP2012517814A patent/JP5689875B2/ja not_active Expired - Fee Related
- 2010-06-28 PL PL10728558T patent/PL2448933T3/pl unknown
- 2010-06-28 CA CA2764425A patent/CA2764425C/en not_active Expired - Fee Related
- 2010-06-28 SG SG2011097128A patent/SG177413A1/en unknown
- 2010-06-28 AU AU2010266537A patent/AU2010266537B2/en not_active Ceased
- 2010-06-28 MX MX2011014024A patent/MX2011014024A/es active IP Right Grant
- 2010-06-28 WO PCT/US2010/040125 patent/WO2011002696A1/en not_active Ceased
-
2011
- 2011-11-25 ZA ZA2011/08707A patent/ZA201108707B/en unknown
- 2011-11-28 IL IL216655A patent/IL216655A/en not_active IP Right Cessation
- 2011-12-12 CR CR20110669A patent/CR20110669A/es not_active Application Discontinuation
- 2011-12-13 TN TNP2011000638A patent/TN2011000638A1/en unknown
- 2011-12-13 GT GT201100321A patent/GT201100321A/es unknown
- 2011-12-22 CO CO11177215A patent/CO6480934A2/es active IP Right Grant
- 2011-12-22 CL CL2011003263A patent/CL2011003263A1/es unknown
- 2011-12-23 EC EC2011011551A patent/ECSP11011551A/es unknown
- 2011-12-26 DO DO2011000405A patent/DOP2011000405A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532106A5 (enExample) | ||
| JP2014501282A5 (enExample) | ||
| HRP20130950T1 (hr) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina | |
| JP2017504576A5 (enExample) | ||
| RU2016123382A (ru) | Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения | |
| JP2013538849A5 (enExample) | ||
| CA2958139A1 (en) | Solid state forms of ibrutinib | |
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| JP2015520140A5 (enExample) | ||
| WO2012088607A1 (en) | Process for treprostinil salt preparation | |
| JP2008505171A5 (enExample) | ||
| CA2948763A1 (en) | Process for making benzoxazepin compounds | |
| CA2796933A1 (en) | 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis | |
| WO2015198227A1 (en) | Co-crystal of dapagliflozin with citric acid | |
| JP2015502371A5 (enExample) | ||
| JP2007505879A (ja) | 既知の抗高脂血症剤の多形体 | |
| JP2009040767A5 (enExample) | ||
| TWI353970B (enExample) | ||
| EP2364307A1 (en) | Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine | |
| AU2019221837B2 (en) | Agents and methods for treating dysproliferative diseases | |
| JP2015512381A5 (enExample) | ||
| JP2018521055A (ja) | サクビトリルカルシウム塩 | |
| HRP20161186T1 (hr) | Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama | |
| JP2019524829A5 (enExample) | ||
| JP2020503330A5 (enExample) |